Araris Biotech AG

2024 has been a year full of progress at Araris in advancing our mission to redefine cancer therapy with our revolutionary multi-payload ADC technology. This past year we: ✅Established multi-warhead ADCs with a higher therapeutic index than conventional mono-warhead ADCs ✅Nominated two specific ADC candidates targeting specific solid tumor types, utilizing our innovative dual and triple payload technology ✅Presented our data of our Napi2b asset at AACR in San Diego ✅Strengthened our IP with our third US patent We are looking forward to even more exciting developments next year, advancing our ADC candidates towards clinical trials, and continue pushing the boundaries of targeted cancer treatment. #Araris #Innovation #CancerResearch #ADCs

Our CEO, Dragan Grabulovski, CSO, Philipp Spycher, and CBO, Filippo Mulinacci will be attending the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco from 13-16 January. If you would like to meet the team to discuss our #ADCtechnology, please contact: info@ararisbiotech.com #Araris #ADC #oncology #Conference #JPM2025

We are pleased to announce our latest publication in ChemBioChem (Chemistry Europe) describing a new technology for developing ADCs that supports our foundational technology platform: https://lnkd.in/e8DXRiyA By enabling the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, Araris is creating a whole new generation of smart missiles. Our revolutionary approach delivers the potency of combination chemotherapy in a targeted fashion in order to tackle the persistent key challenges of cancer resistance and heterogeneity. The publication highlights a process for developing stable, precisely engineered ADCs using small, positively charged peptide linkers. This innovative approach allows direct modification of unmodified, "off-the-shelf" IgG antibodies - a major advance compared to current ADC technologies. The ADCs demonstrated potent anti-cancer activity in vitro and were well-tolerated at high doses in vivo - underscoring the potential of our multi-payload ADCs. #Araris #ADC #oncology #publication #research #ChemBioChem

Next week our CSO Philipp Spycher will be delivering a keynote presentation at PEGS Europe on Wednesday 6 November in Barcelona, Spain.   His presentation, Novel Multi-Payload ADCs Assembled in One Step from Native Antibodies that Show Excellent Biophysical Properties and High Efficacy In Vivo, will take place at 14:20 CET and is part of the oncology stream in the wider protein and antibody engineering summit taking place across three days.   For more information:  https://lnkd.in/e6mb6y8G   #Araris #ADC #oncology #Conference #Summit #Keynote

Next Tuesday, the Araris team will be participating at the Festival of Biologics in Basel. Our CEO, Dragan Grabulovski, will be taking part in a panel at 12:20 CET, while Philipp Probst, Director of ADC Research, is presenting at 15:40 CET and Romain BERTRAND, Director of ADC Chemistry, will present at 17:50 CET. Join us and other industry leaders for in-depth conversations about how to accelerate the development of ADCs and bioconjugates, new linker technologies and improving the stability and payload capacity of ADCs. If you are attending and would like to connect with Dragan, Philipp or Romain please email: info@ararisbiotech.com   To find out more information, follow: Festival of Biologics Agenda 2024 (terrapinn.com) #Araris #ADC #Panel #Conference #Networking #ADCTechnology 

We are pleased to see our innovative approach to multi-payload ADCs featured in a recent article in Bioprocess Online! Our CSO, Philipp Spycher, discusses how our next generation ADC technology has the potential to address the key challenges in oncology: cancer heterogeneity and resistance. Check out the full article to learn about our novel technology and our plans to advance into the clinic: Araris Doubles Down With Dual-payload ADC (bioprocessonline.com) #Araris #ADC #AntibodyDrugConjugates #ADCTechnology #Clinic 

Our CEO, Dragan Grabulovski, was recently interviewed by Brad Loncar from BiotechTV at our labs near Zurich.   During their conversation, Dragan described how Araris Biotech is pioneering the field of ADCs. Due to Araris’ unique ADC linker technology, multiple warheads can be delivered stably to cancer cells to better address their heterogeneity and resistance. He also shared insights into the company’s latest ventures and its future goals.   Check out the full video: https://lnkd.in/gqSUU9_f   #ADC #AntibodyDrugConjugates #ADCTechnology

Today we are excited to announce that we have entered into an agreement with Innate Pharma which sees its portfolio of patents related to its ADC transglutaminase conjugation technology assigned to Araris Biotech AG: https://lnkd.in/eyhrC2WA The newly acquired patents encompass a broad range of intellectual property that cover use of bacterial transglutaminase in conjugating various linker-payloads to antibodies. #ADC #AntibodyDrugConjugates #ADCTechnology #Patents #Agreement

Our CBO, Filippo Mulinacci, will be speaking at the ADC & #Radiopharmaceuticals Pharma & Biotech Partnering Summit September 9-10 in Boston, MA about the potential of our novel #AntibodyDrugConjugate linker technology. For more information and to register, visit here: https://lnkd.in/gkpn-Kpa